Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease-Reference-Cited by-同舟云学术

Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease

Published:2016-02 Issue:4 Volume:117 Page:656-663
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Jain Nishank,Li Xilong,Adams-Huet Beverley,Sarode Ravi,Toto Robert D.^ORCID,Banerjee Subhash,Hedayati S. Susan

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry;Machecourt;J Am Coll Cardiol,2002

2. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?;Jain;Clin J Am Soc Nephrol,2013

3. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis;Aradi;Am Heart J,2010

4. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy;Angiolillo;J Am Coll Cardiol,2010

5. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review on Kidney-Liver Crosstalk: Pathophysiology of Their Disorders;CELL J;2024

2. Updates on New Therapies for Patients with CKD;Kidney International Reports;2024-01

3. Baseline P2Y12 reactivity, kidney function, and CYP2C19 genotype determine clopidogrel responsiveness in acute stroke;Scientific Reports;2023-05-19

4. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease;Vascular Pharmacology;2023-02

5. Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study;Kidney360;2022-12